Janssen to shell out nearly $1 billion for rights to IBD candidate PTG-200

30 May 2017
2019_biotech_test_vial_discovery_big

Janssen Biotech, part of US healthcare giant Johnson & Johnson (NYSE: JNJ), has entered into a worldwide license deal for the co-development and commercialization of PTG-200.

The drug is US biotech firm Protagonist Therapeutics' (Nasdaq: PTGX) first-in-class, oral peptide interleukin (IL)-23 receptor antagonist for all indications including inflammatory bowel disease (IBD), and news of the deal sent the firm’s shares skyrocketing 72.5% to $14.27 in early trading today.

PTG-200 is expected to enter Phase I clinical testing in normal healthy volunteers in the second half of 2017. The agreement builds upon a Johnson & Johnson Innovation – JJDC, Inc Series B venture financing from 2013 in support of the discovery and development of Protagonist's pipeline of oral peptide therapeutics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology